Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher A Green

Showing results (21-30 of 48) with videos related to

Pageof 5
Sort By:
Nature Communications|July 20, 2019
Author Correction: Airway response to respiratory syncytial virus has incidental antibacterial effectsCharles J Sande, James M Njunge, Joyce Mwongeli Ngoi, et al.
Nature Communications|May 19, 2019
Airway response to respiratory syncytial virus has incidental antibacterial effectsCharles J Sande, James M Njunge, Joyce Mwongeli Ngoi, et al.
The Journal of Infection|February 12, 2019
Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adultsChristopher A Green, Charles J Sande, Elisa Scarselli, et al.
Thorax|November 5, 2021
SARS-CoV-2 environmental contamination from hospitalised patients with COVID-19 receiving aerosol-generating proceduresRebecca L Winslow, Jie Zhou, Ella F Windle, et al.
The Lancet. Infectious Diseases|March 12, 2026
A combined ELISA for infection-induced and vaccine-induced mpox antibodies during the clade Ib outbreak in Rwanda: an observational, cross-sectional, clinical validation studyJenny Clarke, Herve Semukunzi, Sian E Faustini, et al.
Science Translational Medicine|August 14, 2015
Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adultsChristopher A Green, Elisa Scarselli, Charles J Sande, et al.
Gut|April 12, 2024
The use of faecal microbiota transplant as treatment for recurrent or refractory <i>Clostridioides difficile</i> infection and other potential indications: second edition of joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelinesBenjamin H Mullish, Blair Merrick, Mohammed Nabil Quraishi, et al.
Plos Neglected Tropical Diseases|August 18, 2016
Using a Human Challenge Model of Infection to Measure Vaccine Efficacy: A Randomised, Controlled Trial Comparing the Typhoid Vaccines M01ZH09 with Placebo and Ty21aThomas C Darton, Claire Jones, Christoph J Blohmke, et al.
BMJ (Clinical Research Ed.)|May 24, 2020
Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort studyAnnemarie B Docherty, Ewen M Harrison, Christopher A Green, et al.
The New England Journal of Medicine|October 29, 2025
Safety, Efficacy, and Immunogenicity of a Salmonella Paratyphi A VaccineNaina McCann, Margarete Paganotti Vicentine, Narges Ebrahimi, et al.
Pageof 5

Showing results (21-30 of 48) with videos related to

Sort By:
Pageof 5
Nature Communications|July 20, 2019
Author Correction: Airway response to respiratory syncytial virus has incidental antibacterial effectsCharles J Sande, James M Njunge, Joyce Mwongeli Ngoi, et al.
Nature Communications|May 19, 2019
Airway response to respiratory syncytial virus has incidental antibacterial effectsCharles J Sande, James M Njunge, Joyce Mwongeli Ngoi, et al.
The Journal of Infection|February 12, 2019
Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adultsChristopher A Green, Charles J Sande, Elisa Scarselli, et al.
Thorax|November 5, 2021
SARS-CoV-2 environmental contamination from hospitalised patients with COVID-19 receiving aerosol-generating proceduresRebecca L Winslow, Jie Zhou, Ella F Windle, et al.
The Lancet. Infectious Diseases|March 12, 2026
A combined ELISA for infection-induced and vaccine-induced mpox antibodies during the clade Ib outbreak in Rwanda: an observational, cross-sectional, clinical validation studyJenny Clarke, Herve Semukunzi, Sian E Faustini, et al.
Science Translational Medicine|August 14, 2015
Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adultsChristopher A Green, Elisa Scarselli, Charles J Sande, et al.
Gut|April 12, 2024
The use of faecal microbiota transplant as treatment for recurrent or refractory <i>Clostridioides difficile</i> infection and other potential indications: second edition of joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelinesBenjamin H Mullish, Blair Merrick, Mohammed Nabil Quraishi, et al.
Plos Neglected Tropical Diseases|August 18, 2016
Using a Human Challenge Model of Infection to Measure Vaccine Efficacy: A Randomised, Controlled Trial Comparing the Typhoid Vaccines M01ZH09 with Placebo and Ty21aThomas C Darton, Claire Jones, Christoph J Blohmke, et al.
BMJ (Clinical Research Ed.)|May 24, 2020
Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort studyAnnemarie B Docherty, Ewen M Harrison, Christopher A Green, et al.
The New England Journal of Medicine|October 29, 2025
Safety, Efficacy, and Immunogenicity of a Salmonella Paratyphi A VaccineNaina McCann, Margarete Paganotti Vicentine, Narges Ebrahimi, et al.
Pageof 5